Trials / Completed
CompletedNCT00981682
Long Term Safety Assessment of SER120 in Patients With Nocturia
A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 376 (actual)
- Sponsor
- Serenity Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SER120 | once a day treatment of nocturia |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-06-01
- Completion
- 2011-08-01
- First posted
- 2009-09-22
- Last updated
- 2021-01-20
- Results posted
- 2021-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00981682. Inclusion in this directory is not an endorsement.